- Home
- Publications
- Publication Search
- Publication Details
Title
The clinical development of MEK inhibitors
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 11, Issue 7, Pages 385-400
Publisher
Springer Nature
Online
2014-05-20
DOI
10.1038/nrclinonc.2014.83
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Allosteric MEK1/2 Inhibitor Refametinib (BAY 86-9766) in Combination with Sorafenib Exhibits Antitumor Activity in Preclinical Murine and Rat Models of Hepatocellular Carcinoma
- (2015) Roberta Schmieder et al. NEOPLASIA
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer
- (2013) C. D. Weekes et al. CLINICAL CANCER RESEARCH
- Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma
- (2013) F. Catalanotti et al. CLINICAL CANCER RESEARCH
- A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
- (2013) Roger B. Cohen et al. EUROPEAN JOURNAL OF CANCER
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
- (2013) Caroline Robert et al. LANCET ONCOLOGY
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
- (2013) Paolo A Ascierto et al. LANCET ONCOLOGY
- TMEM16A alternative splicing coordination in breast cancer
- (2013) Ifeoma Ubby et al. Molecular Cancer
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors
- (2012) S. Leijen et al. CLINICAL CANCER RESEARCH
- Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
- (2012) D. N. Hayes et al. CLINICAL CANCER RESEARCH
- First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors
- (2012) M. Martinez-Garcia et al. CLINICAL CANCER RESEARCH
- 358 A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTOR Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer
- (2012) C. Britten et al. EUROPEAN JOURNAL OF CANCER
- Ocular Toxicity of Targeted Therapies
- (2012) Daniel J. Renouf et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation As a Clinical Marker in Oncology
- (2012) Jean-Pierre Issa JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With MetastaticBRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
- (2012) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET ONCOLOGY
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors.
- (2012) J. C. Bendell et al. MOLECULAR CANCER THERAPEUTICS
- Abstract B128: A phase IB study of the MEK inhibitor GSK1120212 combined with everolimus in patients with solid tumors: Interim results.
- (2012) J. R. Infante et al. MOLECULAR CANCER THERAPEUTICS
- Dropped head syndrome: Report of three cases during treatment with a MEK inhibitor
- (2012) X. Chen et al. NEUROLOGY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)
- (2012) Kenneth D. Rice et al. ACS Medicinal Chemistry Letters
- Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma
- (2011) J. M. Kirkwood et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells
- (2011) Peng Hou et al. ENDOCRINE-RELATED CANCER
- New drugs in melanoma: It’s a whole new world
- (2011) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- MEK inhibitors: a patent review 2008 – 2010
- (2011) John I Trujillo EXPERT OPINION ON THERAPEUTIC PATENTS
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
- (2011) Razelle Kurzrock et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
- (2011) Bert H. O'Neil et al. JOURNAL OF CLINICAL ONCOLOGY
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Reply to M. Keyhani and N. Mahmoudi
- (2011) Hagop Kantarjian JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
- (2011) J. Jing et al. MOLECULAR CANCER THERAPEUTICS
- A full-length 3D structure for MAPK/ERK kinase 2 (MEK2)
- (2011) Hao Liang et al. Science China-Life Sciences
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
- (2010) Kihyun Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
- (2010) Jessie Villanueva et al. CANCER CELL
- Heterogeneous Nuclear Ribonucleoprotein H Blocks MST2-Mediated Apoptosis in Cancer Cells by Regulating a-raf Transcription
- (2010) J. Rauch et al. CANCER RESEARCH
- Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
- (2010) J. R. Dry et al. CANCER RESEARCH
- A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
- (2010) E. B. Haura et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
- (2010) U. Banerji et al. CLINICAL CANCER RESEARCH
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
- (2010) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
- (2010) Charlie Gourley et al. JOURNAL OF CLINICAL ONCOLOGY
- Disclosing the Cancer Diagnosis:The Myth and the Truth
- (2010) Chadi Nabhan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients With Locally Advanced Non–Small-Cell Lung Cancer: Primary Analysis of Radiation Therapy Oncology Group Study RTOG 0214
- (2010) Elizabeth M. Gore et al. JOURNAL OF CLINICAL ONCOLOGY
- From basic research to clinical development of MEK1/2 inhibitors for cancer therapy
- (2010) Christophe Frémin et al. Journal of Hematology & Oncology
- A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens
- (2010) John D. Hainsworth et al. Journal of Thoracic Oncology
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Inhibition of ERK1/2 prevents neural and mesendodermal differentiation and promotes human embryonic stem cell self-renewal
- (2010) Jie Na et al. Stem Cell Research
- Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
- (2009) Thierry O. Fischmann et al. BIOCHEMISTRY
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
- (2009) C. Iverson et al. CANCER RESEARCH
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker
- (2009) L. Lee et al. CLINICAL CANCER RESEARCH
- PD0325901, a Mitogen-Activated Protein Kinase Kinase Inhibitor, Produces Ocular Toxicity in a Rabbit Animal Model of Retinal Vein Occlusion
- (2009) Wenhu Huang et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
- (2009) D. A. Ritt et al. MOLECULAR AND CELLULAR BIOLOGY
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins
- (2008) B. B. Friday et al. CANCER RESEARCH
- The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
- (2008) N. K. Haass et al. CLINICAL CANCER RESEARCH
- Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy
- (2008) B. B. Friday et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started